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Chansu inhibits the expression of cortactin
in colon cancer cell lines in vitro and in vivo
Chun Li1,4, Saeed M. Hashimi1,4, Siyu Cao1,4, Ji Qi1,4, David Good1,2, Wei Duan3 and Ming Q. Wei1,4*
Abstract
Background: Chansu is a transitional Chinese medicine that has been used for centuries as therapy for inflammation,
anaesthesia and arrhythmia in China and other Asian countries. Recently, it has also been used for anti-cancer
purposes. We have previously shown that Chansu has a huge pro-apoptotic potential on colon cancer cells, but to
date the detailed mechanism of this action is not well understood.
Methods: One of the major components of Chansu, Cinobufagin (CBF) was used to treat cancer cells. The expressions
of levels of cortactin, an important factor in tumour progression and cancer invasion, were assessed in in vitro and in
vivo experiments. Additional analyses were performed in subcellular protein fractions and immune-fluorescent
staining was used to define cortactin protein expression and the changes of location in CBF-treated cells.
Results: CBF strongly inhibited the expression of cortactin in HCT116 cells. There were reductions of both mRNA
transcription and protein synthesis, which were more significant in the absence of oxygen in vitro. In addition, nuclear
translocation of cortactin was observed in HCT116 cells post CBF exposure but not in the negative control, indicating
that CBF is likely to interrupt co-localisation of cortactin to cytoskeletal proteins. Most importantly, CBF could diminish
the expression of cortactin in human HCT116 xenograft tumours in nude mouse in vivo.
Conclusions: CBF inhibits cortactin expression and nuclear translocation in colon cancer cells in vitro and in mouse
models bearing human colon tumour in vivo, suggesting it might disrupt actin-regulated cell movement. Thus, CBF
or Chansu could be developed as an effective anti-cancer therapy to stop local invasion and metastasis.
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Background
Chansu is a traditional Chinese medicine extracted from
parotoid glands of the Chinese toad (Bufo gargarizan).
It has been widely used for the treatment of inflamma-
tion, anaesthesia and arrhythmia in China, Japan and
other Asian countries for centuries [1]. Cinobufagin (CBF)
is a major component isolated and purified in the last
decade [2]. The compound possesses a digoxin-like struc-
ture and is a type of sodium/potassium-ATPase inhibitor
(Fig. 1). Recently, other sodium/potassium-ATPase in-
hibitors have also been reported to impair cancer cell
migration through different signalling pathways [3–7].
Cortactin is an important factor involved in cancer cell
progression and invasion [8]. It was initially discovered to
localise to cortical actin at the cell periphery [9]. During
normal cell migration, cortactin is phosphorylated by
Src kinase in the C terminal proline-rich domain, while
Arp2/3 complex binds to the N terminal of cortactin.
The binding of Arp2/3 complex promotes actin polymer-
isation and facilitates the stabilisation of branched actins
[10]. Then the formation of cell motility structures like
lamellipodia supports the movement of certain types of
cells, including osteoclasts and macrophages [11]. Simi-
larly, phosphorylated cortactin is also able to initiate actin
assembly but to form invadopodia in cancer cells, followed
by extracellular matrix (ECM) degradation. As a result,
detached cells invade surrounding tissues. Thus, cortactin
is used as a marker for detection of invadopodia and
enrichment of cortactin indicates the metastatic level in a
number of cancers [12]. Colon cancer is one of the leading
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cancer deaths worldwide and most of the patients died
from metastatic diseases [13]. Previously, overexpression
of cortactin was revealed in a few types of colorectal can-
cers [14]. Compared with normal tissues, primary cancer-
ous colorectal tissues showed assembly of cortactin in
lymph nodes, suggesting a close involvement of cortactin
in metastasis of colorectal cancer cells.
In previous work, we demonstrated that CBF induced
strong apoptosis in colon cancer cells and a hypoxia-
regulated pathway was involved in the drug effect [15].
In the current study, we used CBF as a surrogate marker
for Chansu, and further determined the role of CBF in
the modulation of cortactin expression in human colon
cancer cells. Moreover, we established the effects of CBF
treatment under both hypoxic and normoxic conditions,
as several of these ion pump inhibitors, including digoxin
and ouabain, have been shown to play an anti-cancer role
by diminishing hypoxia-inducible factor 1 alpha (HIF-1α)
expression [16, 17]. Subsequently, mice bearing HCT116
tumour were also used to reveal that CBF induced a re-
duction of cortactin synthesis in tumour tissues. Taken
together, our findings suggest that the mechanism of
Chansu for inhibition of colon cell invasion could be
through blocking the interaction between cortactin and
actin.
Methods
Cell culture and drug treatment
HCT116 and HT29 colon cancer cell lines (provided
kindly by Dr Albert Mellick, Griffith University, Australia)
were maintained in DMEM (Gibco) supplemented with
10 % FBS (HyClone), 2 mM GlutaMAX (Gibco), 100 U/
ml penicillin (Sigma), 100 μg/ml streptomycin (Sigma),
110 mg/L sodium pyruvate (Gibco) and 25 mM HEPES
(Gibco), in an atmosphere of 5 % CO2 and 95 % air at
37 °C. CBF was purchased from Sigma and dissolved
in DMSO (Sigma). 1 μM of CBF solution was applied
in all cell line experiments. To achieve a hypoxic con-
dition, cell lines were sealed in GasPak pouches (BD)
and placed in an incubator at 37 °C.
RNA extraction and real-time RT-PCR
In cell lines, total RNA was isolated at different time
points using a PureLink RNA mini kit (Ambion), accord-
ing to the manufacturer’s instructions. For RNA extrac-
tion from mouse tumour tissues, fresh tissues (<125 mm3)
were initially submerged in RNAlater solution (Ambion)
and stored at 4 °C overnight. The subsequent RNA ex-
traction was carried out by following the instructions
of TRIzol reagent (Ambion). The concentration of all
RNA samples was measured by NanoDrop ND-1000
(Thermo Fisher Scientific). cDNAs of interest were syn-
thesised using SuperScript III RT kit (Invitrogen) accord-
ing to the manufacturer’s instructions. Real-time PCR was
carried out in 20 μl of reaction solution, consisting of
0.4 μM primers (Sigma), 10 μl of Express SYBR GreenER
qPCR SuperMixes (Invitrogen) and ddH2O. Real-time
PCR was performed in iQ5 multicolour real-time PCR
detection system (Bio-Rad). The reaction conditions were
50 °C for 2 min and 95 °C for another 2 min, followed by
40 cycles of 95 °C for 15 s, 60 °C for 1 min. Melting
curves were monitored by heat-denaturing amplicons
over a 35 °C temperature gradient at 0.5 °C/s from 60
to 95 °C. No genomic DNA contamination or pseudo-
genes were detected. Primers used in real-time PCR
were: Human cortactin (Forward: 5′ - AGG TGT CCT
CTG CCT ACC AGA A - 3′, Reverse: 5′ - CCT GCT
CTT TCT CCT TAG CGA G -3′). Human GAPDH
(Forward: 5′ - GTC TCC TCT GAC TTC AAC AGC
G - 3′, Reverse: 5′ - ACC ACC CTG TTG CTG TAG
CCA A - 3′).
Western blotting
Cells were scraped in cold PBS and centrifuged down
(500 × g) to remove methanol. The pellet was resus-
pended in cold RIPA buffer (Pierce), supplemented with
Complete protease inhibitor cocktail tablets (Roche).
After centrifugation at 13,000 × g for 10 min, the super-
natant was collected for further analysis. For protein
extraction from mouse tumour tissues, frozen tissues
were ground in a mortar and pestle and then immersed
in cold RIPA buffer plus protease inhibitor. Further hom-
ogenisation was performed by passing the tissues 5–10
times through a 21-gauge needle. After centrifugation at
13,000 × g for 10 min, the supernatant was collected and
mixed with 1X SDS sample buffer. Protein samples were
loaded onto 7 % or 12 % SDS-PAGE gels, running in Mini
Fig. 1 The molecular structure of CBF. CBF possesses a similar
function as other typical sodium/potassium-ATPase inhibitors
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Trans-Bolt module (Bio-Rad). After gel electrophoresis,
proteins were transferred to PVDF membranes (Millipore).
The membranes were incubated with primary antibodies
against cortactin (1:2000, Abcam) and α-Tubulin loading
control (1:5000, Abcam) overnight at 4 °C after a 45 min
blocking. Horseradish peroxidise-conjugated goat anti-
mouse and anti-rabbit (1:10000, Bio-Rad) secondary
antibodies were applied afterwards. SuperSignal chemilu-
minescent substrate (Pierce) was added to the membranes
which were visualised using a VersaDoc MP4000 system
(Bio-Rad).
Subcellular protein extraction
5 × 106 treated HCT116 cells were detached, centrifuged
down to form a cell pellet and snap frozen in liquid
nitrogen. The subcellular protein extraction followed the
manufacturer’s instructions of ProteoExtract Subcellular
Proteome Extraction Kit (Calbiochem). Briefly, frozen
cell pellets were washed twice in wash buffer and
exposed to Extraction Buffer I plus protease inhibitor
cocktail. After centrifugation, the supernatant was col-
lected as the cytosolic protein fraction and the pellet
was resuspended Extraction Buffer II to isolate the frac-
tion of membrane/organelle proteins. After a series of
centrifugation and usage of specific extraction buffer III ~
IV, the nuclear and the cytoskeletal matrix protein frac-
tions were separated.
Immunocytochemistry
Sterile coverslips were placed in a 24-well plate and
cancer cells were seeded at a density of 1.5 × 105 cells
per well. After overnight incubation at 37 °C, cells were
adherent to the coverslips. Treated cells were washed
in ice cold PBS and fixed in 100 % methanol at −20 °C
for 10 min, followed by washing in ice cold PBS twice,
shaking gently. Usage of 0.2 % Triton X-100 (Sigma) in
PBS to permeabilise samples was for no more than
10 min, followed by 3 times of wash in PBST. Cells were
then blocked in block buffer (3 % normal goat serum and
0.5 % BSA in 0.01 M PBS) for 30 min and sequentially
incubated with primary antibody cortactin (1:300, Abcam)
overnight at 4 °C. The goat anti-rabbit Texas Red (1:1500,
Abcam) secondary antibody was applied in dark for 1 h,
followed a counter DAPI staining (Molecular Probes). All
the coverslips were sealed onto microscope slides using
ProLong Gold antifade reagent (Molecular Probes) and
kept in dark for 24 h. Fluorescence images were visua-
lised using confocal microscope FV1000 (Olympus).
Xenograft establishment and CBF treatment
To establish nude mouse models bearing HCT116 tu-
mour, 5 × 106 HCT116 cells in PBS (200 μl) were
subcutaneously injected into each mouse using 30 - G
needles. After tumour growth for 2 weeks, 14 female
BALB/c nude mice (aged 8 weeks and weighing 16–18 g)
were equally divided into two groups (7 mice per group,
N = 7): intraperitoneal (i.p.) injection and control, with
average tumour size of each group of about 0.32 cm3.
CBF was dissolved firstly in absolute ethanol and diluted
in 10 % propylene glycol solution. To prepare 50 ml
injection solution, 10 mg of CBF was dissolved in 4 ml of
absolute ethanol and diluted in 10 % propylene glycol
solution to reach 0.2 mg/ml. The daily dose given to
i.p. group was 1.5 mg/kg, while an equal amount of
injection solution without CBF was given as a control.
Mice were sacrificed when the tumour grew to 1 cm3.
Tumour tissue specimens were taken for subsequent
RNA and protein analyses. All experiments involving
animals were approved by Griffith University (AEC No.
MSC/01/08).
Results
CBF inhibits mRNA and protein expression of cortactin
in HCT116 cells
Cortactin is overexpressed in colon cancer tissues [18]
and has been shown to be an important factor in tumour
progression and cancer invasion. In this study, we treated
colon cancer cells (HCT116 and HT29) with CBF (1 μM).
In order to mimic the colon cancer microenvironment,
the colon cancer cells were also exposed to hypoxic and
normoxic conditions, respectively (Fig. 2a). Our results
showed that there was a decreased expression of cortactin
mRNA in HCT116 cells under 1 % oxygen. Such a de-
crease was swift, but only lasted less than 24 h, followed
by a significant increase of cortactin transcription. As
the level of oxygen increased to 20 %, the transcrip-
tion of cortactin, however, exhibited an overall reduc-
tion in HCT116 cells within 24 h. On the other hand,
cortactin mRNA level in HT29 cells only slightly altered
during the initial 12 h under different oxygen conditions.
Subsequently, a sharp elevation of mRNA level was
observed at 24 h with 2 folds increase in hypoxia and
almost 5 folds increase in normoxia.
The expression of cortactin protein under hypoxic
conditions was consistent with mRNA message (Fig. 2b).
The inhibition of cortactin at 6 and 12 h in HCT116
cells was significant, but not at 24 h. This inhibitory role
was barely detected in CBF-treated HT29 cells at any
time points. Taken together, our finding showed that
CBF inhibits mRNA and protein expressions of cortactin
in HCT116 cells and this inhibition is swift but not
sustainable. In fact, all the increases of cortactin mRNA
at 24 h time point implied an interference between
CBF-induced inhibition and cortactin transcription. Such
elevated mRNA levels might also result in no down-
regulation of protein expression at 24 h.
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CBF affects distribution of cortactin in HCT116 cells under
hypoxic conditions
To further investigate CBF-induced cortactin inhib-
ition, we examined the subcellular protein expression
in HCT116 cells in hypoxia. Subcellular protein fractions
indicated that the level of cortactin in cytoskeletal fraction
was diminished after CBF treatment, suggesting the dis-
sociation of cortactin and cytoskeletal proteins (Fig. 3a).
Generally, cortactin is localised in the cell periphery.
However, immunostaining showed that CBF exposure
led cortactin to shift towards the nucleus (Fig. 3b).
CBF inhibits mRNA and protein expression of cortactin
in nude mouse models bearing HCT116 tumour
HCT116 cells were implanted in lateral right back of
nude mice (Fig. 4a). When the average of tumour size
reached 0.32 cm3, the CBF treatment started by i.p.
injection. The mice were sacrificed once the tumour
grew to 1 cm3 and tumour tissues were collected. Be-
tween two groups, the average of tumour size was
found to be slightly suppressed by CBF in i.p. group
(Fig. 4b). Moreover, cortactin mRNA level in i.p. group
was significantly reduced (Fig. 4c). The RT-PCR was con-
ducted using mouse tumour tissue samples from different
groups. Interestingly, the protein inhibition was found in
the treatment group (Fig. 4d), demonstrating that CBF
repressed cortactin synthesis in xenografts.
Discussion
Recently, Chansu is being used as an anticancer agent.
Clinical use has shown that it improved the quality of
life in patients with advanced gallbladder cancer [19].
As a major component in Chansu, CBF was used as
surrogate marker to study the mechanism of antican-
cer activity of Chansu. We previously demonstrated that
CBF (1 μM) induced effective apoptosis in colon cancer
cell lines HCT116 and HT29, with 57 % and 30.5 % of
cell death, respectively [15]. We also showed that a key
mediator of cell motility and metastasis, cortactin, was
significantly inhibited by CBF in HCT116 cell line and in
xenografts HCT116 tumours.
Although the overexpression of cortactin in HCT116
cells was identified in previous studies [14, 20], this
Fig. 2 CBF affected cortactin mRNA and protein expression in human colon cancer cell lines HCT116 and HT29. a The mRNA transcription of
cortactin in CBF-treated HCT116 and HT29 cells. 1 μM of CBF was added to HCT116 and HT29 cells which then incubated under hypoxic and
normoxic conditions. The cells were collected at different time points and analysed. Results are means with standard errors from four replicates.
The level of GAPDH as a control was set to 1.0. b Cortactin protein inhibition only in HCT116 cells (1 % oxygen). The expressions of cortactin were
significantly inhibited by CBF in HCT116 cells at 6 h and 12 h, but undetectable in HT29 cells
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report also showed that there is a high level of cortactin
in colon cancer cell line HT29 as well. The inhibition of
transcription and protein levels of cortactin in HCT116
cells was observed in HCT116 but not in HT29 cells,
reflecting that CBF appears to induce strong suppression
in HCT116 cells but has limited efficacy on HT29 cells.
Therefore, CBF is unlikely to strongly target cortactin
in all colon cancer cells. On the other hand, the inhib-
ition occurred swiftly but was overcome within 24 h.
As the half-life of cortactin protein is about 8.9 h [21],
CBF seems to have a fast on-off effect on the protein.
A sharp increase of cortactin mRNA under hypoxic
conditions at 24 h revealed a possibility that the cancer
cells in a hypoxic tumour microenvironment appear to be
able to resistant to CBF. Moreover, the 24 h increase of
cortactin mRNA was detected in both cell lines regardless
to the oxygen levels, suggesting that it could be resulted
from the up-regulation of mitogen-activated protein kin-
ase (MAPK) pathways [22, 23]. Drugs like ouabain and
digoxin have been shown to be capable of activating
MAPK by binding to sodium/potassium-ATPases, result-
ing in the release of Src kinase [22, 23]. As cortactin is a
Fig. 3 CBF changed the distribution of cortactin in HCT116 cells (1 % oxygen). a Subcellular protein extraction of four fractions, which are
cytosolic, membrane/organelle, nucleic and cytoskeletal fractions. Cortactin expression was diminished significantly in the fraction of cytoskeletal
proteins after exposure to 1 μM of CBF. b Co-localisation of cortactin in treated HCT116 cells. Under a hypoxic condition, HCT116 cells were
incubated with 1 μM CBF for 24 h. The subsequent staining revealed a colour overlapping, indicating that CBF induced a nuclear translocation
of cortactin. Scale bars equal 10 μm
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substrate for Src [9], the transcription level of cortactin
could be elevated, followed by abundant expression of
cortactin protein under our assay conditions.
Apart from the in vitro experiments in 1 % oxygen,
the suppression of cortactin was also shown in tissue
samples of nude mice bearing HCT116 tumours. The re-
sults confirmed the inhibitory role of CBF in xenografts
in vivo. Although cortactin inhibition did not sustain in
HCT116 cells within 24 h, CBF is still able to block cor-
tactin synthesis in HCT116 tumour tissues of mouse
models. We hypothesized that this could be due to the
down-regulation of nuclear factor kappa beta (NF-κB),
as Hill et al. elucidated that inhibition of p65 Rel A sub-
unit of NF-κB by IκKinase-2 led to a significant suppres-
sion of cortactin mRNA transcription in breast cancer
MCF7F-B5 cells [24]. Our previous results from
multi-pathway arrays revealed that CBF significantly
impedes NF-κB activity in HCT116 cells [15]. Thus,
the long-term inhibition of cortactin in vivo could be a
consequence of CBF-induced deactivation of NF-κB.
Taken together, our data establishes the inhibitory role of
CBF in cortactin synthesis in a HCT116 cells.
In addition to the general down-regulation of cortactin
protein, the CBF treatment also altered the distribution
Fig. 4 CBF inhibited cortactin synthesis in xenografts. a A nude mouse model bearing HCT116 tumour. The mouse was sacrificed when the
tumour size reached 1 cm3. b Tumour size vs days of treatment (N = 7). Compared with the control, the i.p. group showed a slight suppression
of tumour growth after the drug injection. c Analysis of cortactin mRNA level in tumour tissues. A significant decrease of cortactin mRNA level
presented in i.p. group. Results are means with standard errors from four replicates. The level of GAPDH as a control was set to 1.0. d Abundant
cortactin protein expression only in the control group. The i.p. group showed diminished expression of cortactin. The absence of cortactin in lane
6 of control group was an exemption with an unknown reason
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of cortactin in HCT116 cells under hypoxic conditions.
The nuclear translocation of cortactin in cancer cells
was a new observation. Here, the cause for this shift is
still unclear. Oddly, the total level of cortactin in nucleus
did not boost after the drug exposure, which left a ques-
tion whether cortactin was only dragged to the nucleic
surface and then degraded swiftly. The pioneer work of
Hering and Sheng (2003) showed a nuclear accumula-
tion of cortactin mutant in dendritic spine morphogen-
esis [25]. They discovered that there is a tandem repeat
region within the N-terminal half of cortactin and the
deletion of this region targets cortactin to the nucleus of
dendritic cells rather than dendritic spines. Thus, one
possible explanation for the nuclear import of cortactin
in CBF treated cells is the interruption of the tandem
repeats. Nevertheless, the nuclear translocation of cor-
tactin was not detected in HT29 cells or the tissue
samples from mouse models bearing HCT116 tumours.
Therefore, more investigations of the nuclear import
need to be done in the future.
Conclusions
In conclusion, CBF possess the unique capacity to inhibit
the overexpression of cortactin in HCT116 cells and
nude mouse models bearing HCT116 tumours. It seems
likely that this is the mechanism for Chansu to be used
as an anticancer agent, inhibiting colon cancer cell prolif-
eration and metastasis.
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